Omeprazole has an incidence of adverse events of about 1%; this is about the same as cimetidine and ranitidine. Adverse events of omeprazole reported to the CSM include incidences of:
Omeprazole inhibits one of the metabolic pathways of warfarin and phenytoin and thus monitoring of INR is justified when omeprazole is introduced in patients already taking either or the latter drugs.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.